Literature DB >> 22353997

Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation.

Fanny Guimont-Desrochers1, Geneviève Boucher, Zhongjun Dong, Martine Dupuis, André Veillette, Sylvie Lesage.   

Abstract

The cell lineage origin of IFN-producing killer dendritic cells (IKDCs), which exhibit prominent antitumoral activity, has been subject to debate. Although IKDCs were first described as a cell type exhibiting both plasmacytoid DC and natural killer (NK) cell properties, the current view reflects that IKDCs merely represent activated NK cells expressing B220, which were thus renamed B220+ NK cells. Herein, we further investigate the lineage relation of B220+ NK cells with regard to other NK-cell subsets. We surprisingly find that, after adoptive transfer, B220- NK cells did not acquire B220 expression, even in the presence of potent activating stimuli. These findings strongly argue against the concept that B220+ NK cells are activated NK cells. Moreover, we unequivocally show that B220+ NK cells are highly proliferative and differentiate into mature NK cells after in vivo adoptive transfer. Additional phenotypic, functional, and transcriptional characterizations further define B220+ NK cells as immediate precursors to mature NK cells. The characterization of these novel attributes to B220+ NK cells will guide the identification of their ortholog in humans, contributing to the design of potent cancer immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22353997     DOI: 10.1182/blood-2011-11-395954

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Cutting Edge: Induction of Inflammatory Disease by Adoptive Transfer of an Atypical NK Cell Subset.

Authors:  Elisaveta Voynova; Chen-Feng Qi; Bethany Scott; Silvia Bolland
Journal:  J Immunol       Date:  2015-06-24       Impact factor: 5.422

2.  Expansion of an atypical NK cell subset in mouse models of systemic lupus erythematosus.

Authors:  Elisaveta N Voynova; Jeffrey Skinner; Silvia Bolland
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

Review 3.  Immunological off-target effects of imatinib.

Authors:  Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

4.  Whole blood stimulation with Toll-like receptor (TLR)-7/8 and TLR-9 agonists induces interleukin-12p40 expression in plasmacytoid dendritic cells in rhesus macaques but not in humans.

Authors:  G Koopman; N Beenhakker; S Burm; O Bouwhuis; J Bajramovic; V Sommandas; G Mudde; P Mooij; B A 't Hart; W M J M Bogers
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

Review 5.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

6.  CD56 marks human dendritic cell subsets with cytotoxic potential.

Authors:  Dessie Roothans; Evelien Smits; Eva Lion; Jurjen Tel; Sébastien Anguille
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

7.  Natural killer cells in non-hematopoietic malignancies.

Authors:  Mélanie Desbois; Sylvie Rusakiewicz; Clara Locher; Laurence Zitvogel; Nathalie Chaput
Journal:  Front Immunol       Date:  2012-12-24       Impact factor: 7.561

8.  Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

Authors:  Nathalie Chaput; Caroline Flament; Clara Locher; Mélanie Desbois; Annie Rey; Sylvie Rusakiewicz; Vichnou Poirier-Colame; Patricia Pautier; Axel Le Cesne; Jean-Charles Soria; Angelo Paci; Michelle Rosenzwajg; David Klatzmann; Alexander Eggermont; Caroline Robert; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

9.  Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells.

Authors:  Kyle A Wilson; Stephen R Goding; Harold R Neely; Kristina M Harris; Paul Andrew Antony
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 10.  Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells.

Authors:  Fanny Guimont-Desrochers; Sylvie Lesage
Journal:  Front Immunol       Date:  2013-12-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.